Aligos Q2 net loss narrows to $1.5M; cash runway through Q4 2026

Aligos Therapeutics, Inc.

Net loss of $1.5M ($0.14 per share) vs $15.9M ($1.53) in Q2 2025; improvement driven by $3.0M warrant fair value gain.
Cash, equivalents and investments $30.4M at June 30, 2026, down from $77.8M at Dec 31, 2025; expects funding through Q4 2026.
Received $25M upfront from Amoytop for Greater China license of pevifoscorvir sodium; $3M milestone from ALG-170675 IND approval expected Q3 2026.
Phase 2 B-SUPREME study of pevifoscorvir sodium fully enrolled (245 participants); topline data expected late Q3 2027.
R&D expenses rose to $24.1M from $14.0M due to Phase 2 trial costs; G&A flat at $5.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.